MX2009004143A - Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico. - Google Patents

Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico.

Info

Publication number
MX2009004143A
MX2009004143A MX2009004143A MX2009004143A MX2009004143A MX 2009004143 A MX2009004143 A MX 2009004143A MX 2009004143 A MX2009004143 A MX 2009004143A MX 2009004143 A MX2009004143 A MX 2009004143A MX 2009004143 A MX2009004143 A MX 2009004143A
Authority
MX
Mexico
Prior art keywords
preventing
metabolic syndrome
water
cellulose derivatives
soluble cellulose
Prior art date
Application number
MX2009004143A
Other languages
English (en)
Inventor
Stephanie K Lynch
Maciej Turowski
Wallace H Yokoyama
Jerry R Conklin
Yun-Jeong Hong
Shao-Ching Hung
Scott A Young
Original Assignee
Dow Global Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc filed Critical Dow Global Technologies Inc
Publication of MX2009004143A publication Critical patent/MX2009004143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Los derivados de celulosa solubles en agua son útiles en métodos para prevenir o tratar síndromes metabólicos o un síntoma o una condición asociados con el síndrome metabólico en un individuo; y, en particular, para prevenir o tratar uno o más de los síntomas de: a) hipertensión; b) estado proinflamatorio o de inflamación, y c) estado protrombótico.
MX2009004143A 2006-10-20 2007-10-18 Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico. MX2009004143A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85338806P 2006-10-20 2006-10-20
PCT/US2007/081787 WO2008051794A2 (en) 2006-10-20 2007-10-18 Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome

Publications (1)

Publication Number Publication Date
MX2009004143A true MX2009004143A (es) 2009-11-26

Family

ID=39205140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004143A MX2009004143A (es) 2006-10-20 2007-10-18 Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico.

Country Status (8)

Country Link
US (2) US20110071107A1 (es)
EP (1) EP2079476B1 (es)
JP (2) JP2010506957A (es)
CN (1) CN101686994B (es)
AU (1) AU2007309226B2 (es)
CA (1) CA2666670A1 (es)
MX (1) MX2009004143A (es)
WO (1) WO2008051794A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230439A1 (en) * 2008-10-17 2011-09-22 Kerr Anderson Methods of reducing absorption of trans fatty acids using water-soluble cellulose derivatives
US20100331278A1 (en) * 2009-05-08 2010-12-30 Anderson W H Kerr Uses of cationic hydroxyethylcellulose in oral ingestion forms, and prevention and treatment of metabolic disorders
CN104208713B (zh) * 2013-06-03 2018-04-27 信越化学工业株式会社 用于热熔挤出的组合物以及用其制备热熔挤出产品的方法
CN110366425A (zh) 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
CN108210906A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 治疗冠状动脉粥样硬化及其并发症的药物及其用途
CA3047181A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method and drug for preventing and treating obesity
CN116075240A (zh) * 2020-08-26 2023-05-05 阿波卡-阿格里科拉共同股份公司 用于治疗代谢综合征的具有新兴特性的新系统

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923981A (en) 1982-09-03 1990-05-08 Sbp, Inc. Use of parenchymal cell cellulose to improve comestibles
SE466130B (sv) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande dietfiberkomposition
JP3436537B2 (ja) * 1991-03-01 2003-08-11 ユニヴァーシティ オブ ミシガン 水溶性高粘度品位セルロースエーテルの薬剤組成物とその使用
US5576306A (en) 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5281584A (en) * 1992-02-28 1994-01-25 The Dow Chemical Company Effect of particle-size distribution of cellulose ethers on palatability of compositions
WO1997007689A1 (en) * 1995-08-23 1997-03-06 Moss Clive B High fibre, low calorie, dietary composition
US5766638A (en) * 1995-12-08 1998-06-16 The Dow Chemical Company Hydroxypropyl methocellulose ether compositions for reduction of serum lipid levels
GB9609171D0 (en) * 1996-05-02 1996-07-03 Orion Yhtymae Oy Antioxidant compounds
CA2275902A1 (en) * 1996-12-23 1998-07-02 The Dow Chemical Company Palatable hydroxypropyl methylcellulose ether powder with specified particle size
SE9700983D0 (sv) * 1997-03-18 1997-03-18 Ascendia Ab Stimulering, odling och preservation av pankreas- och andra celler
US6762171B1 (en) * 1999-09-24 2004-07-13 Kyorin Pharmaceutical Co, Ltd. Fatty acid CoA thioester inhibitory substance of PPARα and PPARγ
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
DE10160409A1 (de) * 2001-12-10 2003-06-18 Guenther Beisel Verwendung von ionischen und nichtionischen Celluloseethern zur Herstellung eines gelartigen Mittels zur Verhinderung der Resorption von Fetten aus dem Magen-Darm-Trakt
US6899892B2 (en) * 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
US20040115637A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of PPAR-alpha expression
US20040087514A1 (en) 2002-09-06 2004-05-06 Hughes Thomas E Nutritional compositions
PL209905B1 (pl) 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
KR100752244B1 (ko) * 2005-02-16 2007-08-27 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 약제 조성물
JP2006257064A (ja) * 2005-03-16 2006-09-28 Oriza Yuka Kk 脂質吸収抑制用組成物
US20100247664A1 (en) * 2006-10-20 2010-09-30 Lynch Stephanie K Method of preventing or treating metabolic syndrome

Also Published As

Publication number Publication date
JP2014037422A (ja) 2014-02-27
AU2007309226B2 (en) 2012-09-20
CN101686994B (zh) 2013-05-01
JP2010506957A (ja) 2010-03-04
WO2008051794A2 (en) 2008-05-02
CN101686994A (zh) 2010-03-31
US20090093442A1 (en) 2009-04-09
AU2007309226A1 (en) 2008-05-02
US20110071107A1 (en) 2011-03-24
CA2666670A1 (en) 2008-05-02
EP2079476B1 (en) 2014-05-21
EP2079476A2 (en) 2009-07-22
WO2008051794A3 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
MX2009004143A (es) Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico.
MX2010004488A (es) Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
EP2020100A4 (en) STAND-ALONE STATISTICS APPARATUSES, SYSTEMS, AND METHODS
WO2006105527A3 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
WO2008118197A3 (en) Disabled state and state signaling for link aggregation
MX2010004502A (es) Metodos para tratar trastornos neurologicos urogenitales usando toxinas clostridiales modificadas.
EP1850484A4 (en) EASY MATRIX BASED ON IRREGULAR LDCP, CODEC AND PRODUCTION METHOD THEREFOR
TW200643212A (en) Gas injector and apparatus including the same
NO20084253L (no) Tetrahydroisokinolinderivater for a forbedre hukommelsesfunksjon
EP1843512A4 (en) SIGNATURE GENERATION DEVICE, KEY GENERATION DEVICE AND SIGNATURE GENERATION PROCESS
WO2005077365A3 (en) Novel uses for proton pump inhibitors
NO20060480L (no) Nano-baserte anordninger til bruk i en bronn
WO2009058995A3 (en) Latch structure and self-adjusting pulse generator using the latch
WO2007112279A3 (en) Resonators
DE602007001181D1 (de) Iridiumkomplex, Carbazolderivate und Copolymer damit
RS53586B1 (en) DERIVATION OF DECISION
TW200942560A (en) Conjugated copolymer
CA125603S (en) Infant wrap
WO2008088582A3 (en) Methods and materials related to trail isoforms
UA110484C2 (ru) Целюлозний матеріал, такий як тютюн, що містить один або декілька розріджувачів диму
EP1975712A3 (en) Positive resist composition and pattern forming method using the same
MXPA04003851A (es) Antipruriticos.
CA118576S (en) Shredder device
WO2006128169A3 (en) Inhibition of monocyte survival, differentiation, or proliferation

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration